EXERKINE - Key Persons
Job Titles:
- Director
- Member of the Board
Dan Wright, CPA, MBA, is the CEO of WDW Management Services. He is a seasoned business leader having built several successful companies throughout his career. He is active on several not-for-profit organizations boards and is currently acting Vice Chairman for the United Mitochondrial Disease Foundation.
Job Titles:
- Director
- Member of the Board
- Professor of Environmental Sustainability
Dr. Mike Waddington, PhD, is a Professor of Environmental Sustainability and Resilience at McMaster University. He is the president of Peaterra, an environmental consulting firm working with the Canadian resource sector on post-mining ecosystem restoration and reclamation.
Job Titles:
- Chairman of the Board
- Director
Mark Tamminga, LL.B., MBA, is a Senior Partner at Gowling Lafleur Henderson, LLP, one of Canada's largest law firms. He served as Managing Partner for the firm's Hamilton office from 2008 to 2011. In 2012 he took on the role of Leader, Innovation Initiatives. He current serves as Chairman of the Board for Exerkine.
Job Titles:
- Chief Executive Officer
- Chief Scientific Officer
- Director
- Founder
- President
Mark Tarnopolsky founded Exerkine in 2013 to develop a new class of therapies that promise a dramatic improvement in the lives of patients. Dr. Tarnopolsky holds an endowed chair at McMaster Children's Hospital and Hamilton Health Sciences Foundation in Neuromuscular Diseases and is a Professor of Pediatrics and Medicine. He completed a PhD in cell biology and metabolism and residency training in Internal Medicine, Neurology and Physiatry. He is also a fellow of the American Academy of Electrodiagnostic Medicine.
Dr. Tarnopolsky has received numerous awards and recognitions, such as the David Green Award from the Muscular Dystrophy Association in 2005, the Barsky Lectureship for Excellence in Mitochondrial Medicine in 2007, and the Honour Award from the Canadian Society for Exercise Physiology in 2008. He has devoted his career to studying the impact of nutrition, exercise and drug therapies for genetic and aging-associated diseases. In addition to his role as a researcher and clinician, Dr. Tarnopolsky has also spent the last 20 years of his career acting as a consultant to pharmaceutical industry, as well as co-founding and serving as a chief scientific officer to Life Science Nutraceuticals.